Malignant pleural mesothelioma.

Area of Science:

• Oncology
• Thoracic Surgery
• Medical Oncology

Background:

• Malignant pleural mesothelioma (MPM) treatment is difficult, with limited success for surgery, radiotherapy, and chemotherapy.
• Most patients experience disease progression and respiratory failure, necessitating systemic therapy as the primary option.
• Evaluating chemotherapy efficacy in MPM is hindered by small patient numbers, lack of randomization, disease heterogeneity, and challenges in response assessment.

Purpose of the Study:

• To review the current landscape of systemic chemotherapy for malignant pleural mesothelioma.
• To identify effective chemotherapeutic agents and regimens for MPM treatment.
• To discuss the challenges and future directions in MPM therapy.

Main Methods:

• Review of existing literature on chemotherapy for malignant pleural mesothelioma.
• Analysis of response rates and outcomes for various chemotherapeutic agents and combinations.
• Discussion of novel therapeutic strategies and ongoing research.

Main Results:

• No single intervention has significantly impacted most malignant pleural mesothelioma patients.
• Gemcitabine in combination with cisplatin demonstrated a 48% response rate in a phase II study, becoming a new standard for off-protocol treatment.
• While historically doxorubicin was standard, its response rate is only 15%; gemcitabine shows greater activity, especially with platinums.

Conclusions:

• Systemic chemotherapy is the main treatment option for most malignant pleural mesothelioma patients.
• The combination of gemcitabine and cisplatin represents a promising regimen, though validation is needed.
• Emerging agents and combination therapies offer hope for improved outcomes in malignant pleural mesothelioma.